# Moshe Phillip

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/moshe-phillip/

## Facts

| Field | Value |
| --- | --- |
| Citations | 28,795 |
| Field | Diabetes Management and Research |
| h-index | 79 |
| i10-index | 299 |
| Last Known Institution | Tel Aviv University |
| OpenAlex ID | https://openalex.org/A5026948710 |
| ORCID iD | https://orcid.org/0000-0002-6616-5612 |
| Works | 601 |

## Researcher papers

- [Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range](https://scholariq.org/papers/clinical-targets-for-continuous-glucose-monitoring-data-interpretation/)
- [International Consensus on Use of Continuous Glucose Monitoring](https://scholariq.org/papers/international-consensus-on-use-of-continuous-glucose-monitoring/)
- [Nocturnal Glucose Control with an Artificial Pancreas at a Diabetes Camp](https://scholariq.org/papers/nocturnal-glucose-control-with-an-artificial-pancreas-at-a-diabetes-camp/)
- [Consensus Recommendations for the Use of Automated Insulin Delivery Technologies in Clinical Practice](https://scholariq.org/papers/consensus-recommendations-for-the-use-of-automated-insulin-delivery-technologies/)
- [Use of Insulin Pump Therapy in the Pediatric Age-Group](https://scholariq.org/papers/use-of-insulin-pump-therapy-in-the-pediatric-age-group/)
- [Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial](https://scholariq.org/papers/efficacy-and-safety-of-dapagliflozin-in-patients-with-inadequately-controlled/)
- [A Glycemia Risk Index (GRI) of Hypoglycemia and Hyperglycemia for Continuous Glucose Monitoring Validated by Clinician Ratings](https://scholariq.org/papers/a-glycemia-risk-index-gri-of-hypoglycemia-and-hyperglycemia-for-continuous/)
- [Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study](https://scholariq.org/papers/efficacy-and-safety-of-dapagliflozin-in-patients-with-inadequately-controlled-3/)
- [Insulin dose optimization using an automated artificial intelligence-based decision support system in youths with type 1 diabetes](https://scholariq.org/papers/insulin-dose-optimization-using-an-automated-artificial-intelligence-based/)
- [ISPAD Clinical Practice Consensus Guidelines 2018: Insulin treatment in children and adolescents with diabetes](https://scholariq.org/papers/ispad-clinical-practice-consensus-guidelines-2018-insulin-treatment-in-children/)
- [Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial](https://scholariq.org/papers/anti-interleukin-21-antibody-and-liraglutide-for-the-preservation-of-cell/)

## Researcher topics

- [Diabetes Management and Research](https://scholariq.org/topics/diabetes-management-and-research/)
- [Pancreatic function and diabetes](https://scholariq.org/topics/pancreatic-function-and-diabetes/)
- [Diabetes and associated disorders](https://scholariq.org/topics/diabetes-and-associated-disorders/)
- [Growth Hormone and Insulin-like Growth Factors](https://scholariq.org/topics/growth-hormone-and-insulin-like-growth-factors/)
- [Hyperglycemia and glycemic control in critically ill and hospitalized patients](https://scholariq.org/topics/hyperglycemia-and-glycemic-control-in-critically-ill-and-hospitalized-patients/)

## Researcher university

- [Tel Aviv University](https://scholariq.org/institutions/tel-aviv-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.